Bacterial infections induce exacerbations in chronic lung diseases, e.g., chronic obstructive pulmonary disease (COPD), by enhancing airway inflammation. Exacerbations are frequently associated with right heart decompensation and accelerate disease progression. Endothelin receptor antagonists (ERAs) might have therapeutic potential as pulmonary vasodilators and anti-inflammatory agents, but utility in exacerbations of chronic lung diseases is unknown. We hypothesized that cytokine releases induced by lipopolysaccharide (LPS), the major bacterial trigger of inflammation, are reduced by ERAs in pulmonary vascular smooth muscle cells (PVSMCs). Ex vivo cultivated human PVSMCs were preincubated with the endothelin-A-receptor selective inhibitor ambrisentan, with the endothelin-B-receptor selective inhibitor
Introduction
Airway inflammation drives progression of chronic inflammatory lung diseases, such as chronic obstructive pulmonary disease (COPD) (Barnes 2008a; Stockley, 2009) . Airway infections with Gram-negative bacteria induce exacerbations in COPD and other chronic lung diseases (Jackson et al., 2011; Decramer et al., 2012) . This aggravates inflammation and inflammation-induced airway remodeling, leading to accelerated disease progression including the development of comorbidities (Barnes 2008a; Stockley, 2009; Decramer et al., 2012) . This work was funded by Actelion Pharmaceuticals, Germany. Actelion Pharmaceuticals was not involved in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.
J.K. has received travel grants from Actelion Pharmaceuticals. D.J. has received travel grants from Actelion Pharmaceuticals and from GlaxoSmithKline. J.B. has received travel grants, fees for speaking and research grants from Actelion Pharmaceuticals, fees for speaking from GlaxoSmithKline, and has served as consultant/advisor for Actelion Pharmaceuticals and GlaxoSmithKline. A.K. has received travel grants from Actelion Pharmaceuticals and from GlaxoSmithKline and research funding from Actelion Pharmaceuticals. dx.doi.org/10.1124/jpet.112.202358 COPD patients with pulmonary hypertension (PH) have more frequent exacerbations, and inflammation contributes to PH (Price et al., 2012; Wells et al., 2012) . Therefore, inflammation might contribute to the pathogenesis of right heart failure in acute exacerbations of COPD. As therapies for exacerbations in chronic lung diseases are insufficient, alternative therapeutic strategies are required (Adcock and Barnes, 2008) . Pulmonary vascular smooth muscle cells (PVSMCs) are involved in airway remodeling in chronic inflammatory lung diseases and drive vascular remodeling in PH (Dupuis and Hoeper, 2008; Barbera and Blanco, 2009; Al-Muhsen et al., 2011) . They contribute to inflammation during bacterial infection by releasing cytokines in response to lipopolysaccharide (LPS), which is the major inflammatory trigger synthesized by Gram-negative bacteria (Gatheral et al., 2012) . Therefore, PVSMCs might contribute to the link between infection-induced inflammation and vascular remodeling associated with the development of PH as a comorbidity in chronic inflammatory lung diseases such as COPD. This renders PVSMCs interesting therapeutic targets in early disease stages regarding the reduction of inflammation-induced airway vascular remodeling in consequence of infection-caused exacerbations.
PVSMCs express both subtypes of endothelin receptors, ET A R and ET B R (Henno et al., 2009) . Two types of ERAs are approved in therapy of PH: ET A R-selective blockers, namely ambrisentan, and nonselective/dual blockers, such as bosentan. However, studies comparing the efficacy of ET A Rselective versus dual blockers are missing. Endothelin-1 does not only trigger remodeling but also inflammation (Dupuis and Hoeper, 2008) . ERAs have anti-inflammatory and antifibrotic potential in bronchial smooth muscle cells: they reduce the TNFa-induced release of cytokines/chemokines and remodeling proteins (Knobloch et al., 2009 (Knobloch et al., , 2013 . This was the first evidence for roles of ET A R and ET B R in inflammation-induced remodeling processes. From this, we hypothesized that the anti-inflammatory properties of ERAs could have a utility in early stages of chronic lung diseases with regard to attenuating inflammation-induced remodeling processes and the consequential development of comorbidities like PH.
Here, we aimed to support this hypothesis by means of clinical basic research. We focused on the question whether ERAs might suppress the inflammatory response of PVSMCs to bacterial infection, which is critical in disease exacerbations and promotes remodeling. Given the importance of LPS in infection-induced inflammation, LPS-stimulated PVSMCs are a suitable cell culture model for addressing this question. We further aimed to investigate the underlying mechanisms for putative anti-inflammatory effects of ERAs. This requires consideration of the specific characteristics of the response of PVSMCs to LPS and of the receptors involved. LPS sensitivity is inconsistent among different human arterial vascular smooth muscle cell preparations (Yang et al., 2005) : VSMCs from coronary arteries recognize LPS via the TLR4/CD14 receptor complex on their surface. However, PVSMCs do not express membrane-bound CD14 (mCD14), although CD14 mRNA is detectable. Nonetheless, LPS induces cytokine release in PVSMCs (Gatheral et al.; , suggesting that soluble CD14 (sCD14) might compensate for the lack of mCD14, as it has been shown for other cell types including VSMCs of venous origin (Loppnow et al., 1995; Bäckhed et al., 2002) .
Complete LPS (smooth LPS, S-LPS) consists of lipid A, a core oligosaccharide and an O-polysaccharide (King et al., 2009) . Some bacteria that are relevant for exacerbations in chronic lung diseases synthesize truncated forms (rough LPS) with oligosaccharide structures in different degrees of completion. Re-LPS, the shortest form, lacks the O-polysaccharide and has the most incomplete core oligosaccharide (Huber et al., 2006) . For example, Pseudomonas aeruginosa strains, which are frequently found in COPD patients, synthesize a broad spectrum from S-LPS to shortest rough LPS forms (Bantroch et al.,1994; King et al., 2009 ). This suggests that the whole LPS spectrum has clinical relevance. Whereas S-LPS requires mCD14 or sCD14 to activate TLR4, this CD14 dependence diminishes with increasing degrees of LPS truncation. Re-LPS activates TLR4 completely independent from CD14 (Huber et al., 2006) .
We hypothesized that PVSMCs differentially respond to both S-LPS and Re-LPS with the release of IL-6, IL-8, and GM-CSF, all of which are important for inflammation-induced remodeling. We further hypothesized that selective and dual ERAs differentially suppress LPS-induced cytokine release from PVSMCs by interfering with TLR4 signaling and, therefore, could be considered candidate drugs for attenuating bacteria-induced inflammation in exacerbations of chronic lung diseases.
Materials and Methods
Human PVSMC Isolation and Cultivation. Human PVSMCs were dissected from main pulmonary artery explants from patients (4 women, 2 men) undergoing lung resection for carcinoma of the bronchus as described previously (Peng et al., 1996) . For PVSCM isolation, healthy tumor-free tissue was used. In brief, the arteries were separated from their adventitia and endothelium and then cut into 1-to 3-mm 2 pieces with sterile scalpel blades. These tissue pieces were incubated for 30 minutes at 37°C and 5% CO 2 in Hanks' balanced salt solution (H6648; Sigma-Aldrich, St. Louis, MO) containing 10 mg/ml bovine serum albumin (BSA; A0281; SigmaAldrich) and the enzymes collagenase (type XI, 1 mg/ml; C9407; Sigma-Aldrich) and elastase (type I, 3.3 U/ml; E7885; Sigma-Aldrich). Tissue pieces were then incubated for a further 30-60 minutes in the enzyme solution outlined above with elastase content increased to 15 U/ml. To separate the dispersed cells from the enzyme solution they were centrifuged (100g, 5 minutes) at 4°C and then resuspended in Dulbecco's modified Eagle's medium (DMEM; 31885-023; Invitrogen, Karlsruhe, Germany) with 10% fetal calf serum (N-4637; SigmaAldrich), sodium pyruvate (1 mM; 11360-039; Invitrogen), L-glutamine (2 mM; G-7513; Sigma-Aldrich), nonessential amino acids (1%; 11140-035; Invitrogen), penicillin (100 U/ml), streptomycin (100 mg/ ml; P-4333; Sigma-Aldrich), and amphotericin B (1.5 mg/ml; A-2942; Sigma-Aldrich). The PVSMC cellular suspension was placed in a tissue culture flask (25 cm 2 ; 156367; Nunc, Roskilde, Denmark) with 8 ml of supplemented DMEM and incubated in a humidified atmosphere at 37°C in 5% CO 2 . The culture medium was replaced after 4-5 days and subsequently every 2-3 days. After 4-8 weeks the cells reached confluence. Subconfluent cells were passaged with trypsin (1% in Hanks' balanced salt solution; T-4674; Sigma-Aldrich). This study was approved by the ethics committee of the University of Bochum (4257-12), Germany, and all patients gave their written consent.
PVSMC Characterization. PVSMCs were characterized by positive immunostaining for smooth muscle a-actin (SMA) and myosin heavy chain (MHC). Fluorescence-based immunostaining was done as described before (Knobloch et al., 2007) . In brief, cells were seeded on coverslips in six-well plates (83.1839; Sarstedt,
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Nümbrecht, Germany) in DMEM with supplements as described above. After 16 hours, the medium was removed, and the cells were washed in phosphate-buffered saline (PBS; P4417; Sigma-Aldrich) and fixed on the coverslips with 4% paraformaldehyde in PBS for 60 minutes at 4°C. Cells were washed three times in PBS [3 minutes at room temperature (RT)], incubated for 10 minutes in PBS 1 0.5% Triton X-100 (112298; Merck, Darmstadt, Germany) at RT, and then washed three times in PBS 1 0.1% Triton X-100 (PBT; 3 minutes, RT). Blocking was done with 10% fetal calf serum in PBT for 30 minute at RT. Cells were then incubated with primary antibodies against a-smooth muscle actin (SMA) (mouse anti-human SMA, clone 1A4; A5228; Sigma-Aldrich) or smooth muscle myosin heavy chain (SMMHC) (mouse anti-human SM-1 and SM-2, clone h-SM-V; M7786; Sigma-Aldrich) diluted 1:100 or 1:400, respectively, in blocking solution for 2 hours. Cells were washed five times in PBT (2 minutes, RT) and then incubated with a goat anti-mouse IgG Cy3-coupled secondary antibody (115-165-003; Dianova, Hamburg, Germany) diluted 1:100 in blocking solution for 30 minutes at RT in the dark. Cells were then washed five times in PBT (3 minutes, RT). Counterstaining with 49,6-diamidino-2-phenylindole (0.1 mg/ml; D9542; Sigma-Aldrich) was done for 15 minutes at RT in the dark. Cells were washed three times with PBT and one time with PBS (each 3 minutes at RT in the dark). Cells were mounted in Dako fluorescent mounting medium (S3023; Dako, Hamburg, Germany) and analyzed by fluorescence microscopy. Cells were .95% positive for SMA and MHC. Cell viability was assessed by counting cells after staining with trypan blue (15250; Invitrogen) in a Neubauer hemocytometer. Cell viability was found to be greater than 95%.
PVSMC Stimulation. Before stimulation, subconfluent cell monolayers (∼80% confluence) in six-well cell culture plates at passages 3 to 6 were deprived of serum for 24 hours in serum-free and low glucose (1 g/l) DMEM (41966-029; Invitrogen) supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine, 1% nonessential amino acids, 100 U/ml penicillin, 100 mg/ml streptomycin, 1.5 mg/ml amphotericin B, 1 mM insulin (I1882; Sigma-Aldrich), 5 mg/ml apo-transferrin (T1147; Sigma-Aldrich), and 100 mM ascorbic acid (A4403; Sigma-Aldrich). Subsequent stimulation with different LPS forms and ERAs (see below) was done in serum-free and low glucose (1 g/l) DMEM supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine, 1% nonessential amino acids, 100 U/ml penicillin, 100 mg/ml streptomycin, and 1.5 mg/ml amphotericin B for 4, 16 (for RNA analyses), or 72 hours (for cytokine measurements in cell culture supernatants).
Mixed LPS (M-LPS) preparations (containing undefined amounts of S-LPS and short-chain LPS variants) from Salmonella enteritidis (L7770; Sigma-Aldrich) contained ,1% protein and 10-20% nucleic acids. Preparations of S-LPS from Salmonella minnesota (ALEXIS/ EnzoLifeSciences GmbH, Lörrach, Germany cat# 581-020) and Re-LPS from S. minnesota R595 (581-008; ALEXIS) did not contain detectable protein or DNA contaminants with agonistic TLR activity. According to previous studies (Knobloch et al., 2009 (Knobloch et al., , 2013 , PVSMCs were preincubated for 2 hours with ambrisentan
amino}hexanoate; B157; Sigma-Aldrich] (each at 0.1-10 mM) before stimulation with LPS. According to previous studies (Knobloch et al., 2011a) , PVSMCs were preincubated with polymyxin B [N-[4-amino-1-[[1-[[4-amino-1-oxo-1-[[6,9,18- 5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl] amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide; 1-10 mg/ml; cat no. tlrl-pmb; Invivogen], with CLI-095 [TAK-242, ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate; 1 mM; cat no. tlrl-cli95; Invivogen], with blocking antibodies for TLR2 (10 mg/ml; cat no. pab-hstlr2; Invivogen) or CD14 (1-10 mg/ml; clone biG14; cat no. 021-3c.2; Biometec, Greifswald, Germany), with an isotype control (MAB003; R&D Systems, Wiesbaden, Germany) or with the TLR9-specific inhibitory nucleotide ODN TTAGGG (59-ttt agg gtt agg gtt agg gtt agg g-39; 2.5 mM; Invivogen) 30-60 minutes before stimulation with LPS.
RNA Isolation and Quantitative RT-PCR. DNA-free total RNA was extracted from 80% subconfluent PVSMCs with the chromatographybased RNeasy technique (74106; QIAGEN GmbH, Hilden, Germany). Quantitative RT-PCR (qRT-PCR) was done as described previously (Knobloch et al., 2011a) . In brief, after cDNA synthesis (205113; QIAGEN) with random primers (C1181; Promega, Mannheim, Germany), quantitative PCRs (PCR kit; 203205; QIAGEN) were done with gene-specific and intron-spanning primers. The housekeeping gene EF1a was used as a reference. PCR conditions were established for each primer pair in the exponential range, allowing quantification of signal intensities after ethidium bromide staining and standard agarose gel electrophoresis by densitometry using Alpha Innotech (San Leandro, CA) software, version 1.3.0.7. As a prerequisite for reliable quantification of signal intensities, Alpha Innotech software recognizes oversaturation (e g., attributable to excess loading of the agarose gel) and nonlinear gamma or contrast correction of signals and disables densitometry tools in those cases. Values for TLR4 and CD14 under the different stimulation conditions were normalized to EF1a reference signals to correct for putative differences in RNA/cDNA load. Primer sequences have been published previously (Knobloch et al., 2011a,b) .
ELISA. IL-6, IL-8, GM-CSF, and sCD14 concentrations in cell culture supernatants were measured via ELISA (Duo Sets or Quantikine, R&D systems, catalog nos. DY206, DY208, DY215, DC140) according to standard protocols (Koch et al., 2004; Knobloch et al., 2011a Knobloch et al., , 2011b .
Statistical Analysis of qRT-PCR and ELISA Data. Drug effects on cytokine expression in LPS-stimulated PVSMCs were expressed as percent inhibition versus stimulation with LPS alone. According to previous studies (Knobloch et al., 2010 (Knobloch et al., , 2011b , Gaussian distributions of the data describing LPS and drug effects on cytokine expression in primary cells were expected and were confirmed for all data sets by Kolmogorov-Smirnov tests. Therefore, the data were expressed as mean 6 S.E.M., and parametric tests (with 95% confidence intervals) were used for analyses. a , 0.05 was considered as statistically significant. All calculations were done with GraphPad Prism.
The effects of LPS on cytokine release investigated in concentrationresponse experiments were analyzed by one-way repeated-measures ANOVA tests. If a , 0.05 was reached, post hoc Bonferroni-Holm tests were used to analyze for differences between the data for individual LPS concentrations versus unstimulated controls.
The percent inhibition data for Polymyxin B, CLI-095, aTLR2AB, IgG control antibody, and ODN TTAGGG regarding IL-8 release in M-LPS-treated cells were analyzed for differences to a hypothetical value 0, which stands for no inhibition or stimulation with M-LPS in the absence of inhibitors, respectively, with one-sample t tests and Bonferroni correction for multiple testing.
Concentration response curves showing the reducing effects of ERAs on cytokine release in M-LPS-treated cells were calculated by nonlinear (sigmoidal) regression with variable parameters. The percent inhibition data for each ERA at 10 mM were analyzed for differences to a hypothetical value 0, which stands for no reduction or stimulation with M-LPS in the absence of ERAs, respectively, with one-sample t tests and Bonferroni correction for multiple testing. If a , 0.05 was reached for an ERA, the same analysis was done with the percent inhibition data for this ERA at 1 mM. In addition, the percent inhibition data were analyzed for differences between the three ERAs at the same concentration. This was done by one-way repeated-measures ANOVA tests. If a , 0.05 was reached, post hoc Bonferroni-Holm tests were performed.
The effects of ERAs on sCD14 release as well as on TLR4 and CD14 mRNA levels in the presence and absence of LPS were analyzed by one-way repeated-measures ANOVA. If a , 0.05 was reached, post hoc Bonferroni-Holm tests were performed to analyze for drug effects versus unstimulated and LPS-stimulated cells.
The effects of different concentrations of the CD14 blocking antibody on cytokine release in S-LPS-exposed cells were analyzed by one-way repeated-measures ANOVA tests and, if a , 0.05 was reached, post hoc Bonferroni-Holm tests. The percent inhibition data for each ERA regarding IL-8 release in S-LPS-and Re-LPS-treated cells were analyzed for differences to a hypothetical value 0, which stands for no reduction or stimulation with S-LPS/Re-LPS in the absence of ERAs, respectively, with one-sample t tests and Bonferroni correction for multiple testing. If a , 0.05 was reached for an ERA, its percent inhibition data regarding S-LPS-induced IL-8 release were compared with those regarding Re-LPS-induced IL-8 release with a two-tailed, paired Student's t test.
Results
M-LPS, S-LPS, and Re-LPS Induce Cytokine Release from PVSMCs. There is considerable similarity between LPS forms and spectra of Salmonella sp. and P. aeruginosa, which is frequently isolated in exacerbations of chronic lung diseases (King et al., 2009 ). As it is easily available, LPS from Salmonella has been established as a model LPS in experimental basic research regarding exacerbations of chronic inflammatory lung diseases (Knobloch et al., 2011a) . Thus, we have used LPS from Salmonella sp. to experimentally investigate the responses of PVSMCs to different LPS forms and the effects of ERAs. M-LPS is an undefined mixture of smooth LPS and multiple short-chain LPS forms of S. enteritidis. S-LPS and Re-LPS are pure and defined preparations of smooth LPS or short-chain LPS, respectively, both from S. minnesota. All LPS forms induce a robust release of IL-8, IL-6, and GM-CSF from PVSMCs in a concentration-dependent manner (Fig. 1 ). There were no statistically significant differences between the inductive effects of S-LPS and Re-LPS on all cytokines analyzed (Fig. 1, data not shown) , suggesting that PVSMCs almost equally respond to LPS forms of different length. In contrast to S-LPS and Re-LPS, which are highly purified, M-LPS preparations might contain small amounts of bacterial lipopeptides and nucleic acids, which are putative TLR2 or TLR9 agonists (see Materials and Methods). M-LPS-induced IL-8 release from PVSMCs was completely blocked by polymyxin B, which neutralizes LPS (Morrison and Jacobs, 1976) , and by CLI-095 (TAK-242), a specific inhibitor for TLR4 that binds to its intracellular TIR domain (Kawamoto et al., 2008) , but was not affected by a TLR2 blocking antibody and by ODN TTAGGG (Fig. 2) , a TLR9-specific inhibitory nucleotide (Gursel et al., 2003) . All blocking reagents did not modulate baseline IL-8 release (data not shown). These data confirm that we measured true M-LPS effects and demonstrate that LPS signals via TLR4 to induce cytokine release in PVSMCs.
Endothelin Receptor Antagonists Attenuate LPSInduced Cytokine Release from PVSMCs. The ET A Rselective blocker ambrisentan, the ET B R-specific blocker BQ788, and the dual blocker bosentan did not modulate baseline releases of IL-8, IL-6, or GM-CSF from PVSMCs (data not shown). In the presence of M-LPS, all three ERAs reduced IL-6 release from PVSMCs almost equally (Fig. 3A , Table 1 ). Bosentan and BQ788 reduced IL-8 and GM-CSF release from M-LPS-stimulated PVSMCs almost equally. In contrast, ambrisentan did not modulate IL-8 and GM-CSF in M-LPS-stimulated PVSMCs in a statistically significant manner but showed a trend toward upregulating these two cytokines (Fig. 3, B and C) . This suggests that blocking ET B R might be more effective in reducing LPS-induced cytokine release in PVSMCs than blocking ET A R.
Inhibition of ET B R Reduces CD14 mRNA Levels and sCD14 Release. PVSMCs express TLR4 and CD14 mRNA (Fig. 4 , A-C; Yang et al., 2005) as well as functional TLR4 but are mCD14 negative (Yang et al., 2005) . As PVSMCs responded to S-LPS (Fig. 1, B , E, and H), which requires CD14 to activate TLR4 (Huber et al., 2006) , we speculated that sCD14 might replace mCD14. However, PVSMCs were stimulated with S-LPS in serum-free medium, which did not contain detectable levels of sCD14 in the absence of PVSMCs (data not shown). This suggests that sCD14 might be endogenously released from PVSMCs. Indeed, we were able to detect sCD14 in PVSMC culture supernatants (Fig. 4D) .
Neutralization of sCD14 with a specific blocking antibody (biG14; Dziarski et al., 1998 ) concentration dependently reduced S-LPS-induced IL-6, IL-8, and GM-CSF release (Fig. 5) . This demonstrates that the induction of cytokine release from PVSMCs by long LPS forms depends on the constitutive release of sCD14, which functionally replaces mCD14.
Regulation of cytokine gene expression by LPS/TLR4 signaling does not directly involve endothelin receptors. To elucidate the molecular mechanism responsible for ET B R blockade to reduce LPS-induced cytokine expression, we investigated the effects of ERAs on the expression of TLR4 and sCD14. M-LPS did not modulate TLR4 and CD14 mRNA levels after 4 and 16 hours of stimulation in PVSMCs (Fig. 4 , A-C). All three ERAs did not modulate TLR4 mRNA levels at both time points (Fig. 4, A and B) and did not modulate CD14 mRNA after 4 hours. However, bosentan and BQ788 but not ambrisentan clearly reduced CD14 mRNA levels after 16 hours (Fig. 4, A and C) . According to the mRNA data, M-LPS did not modulate sCD14 release, and bosentan and BQ788 but not ambrisentan suppressed sCD14 release from PVSMCs (Fig. 4D) .
ET B R Blockade Reduces S-LPS-Induced IL-8 Release but Not Re-LPS-Induced IL-8 Release. In contrast to S-LPS, Re-LPS activates TLR4 independent from CD14 (Huber et al., 2006) . M-LPS contains long and short LPS forms, suggesting that the cytokine response to M-LPS is partially but not completely dependent on CD14 (Knobloch et al., 2011a) . Thus, if sCD14 repression by ET B R blockade is a major mechanism explaining the reduction of LPS-induced cytokine expression by bosentan and BQ788, S-LPS-induced but not Re-LPS-induced cytokine expression should be sensitive to these ERAs. We investigated this hypothesis as exemplary for IL-8; indeed, bosentan and BQ788 but not ambrisentan suppressed S-LPS-induced IL-8 release, whereas all three ERAs did not significantly modulate Re-LPS-induced IL-8 release (Fig. 6 ). These data provide evidence that sCD14 suppression caused by ET B R blockade explains the reductive effects of bosentan and BQ788 on LPS-induced cytokine expression in PVSMCs. Barnes, 2008a) . GM-CSF is involved in the pathogenesis of chronic inflammatory lung diseases and might link inflammation with remodeling processes (Barnes 2008a; Knobloch et al., 2009) . Our data suggest that PVSMCs contribute to the enhancement of inflammation during exacerbations induced by bacteria, as they respond to LPS by releasing these cytokines. The PVSMC response to bacterial infections might contribute to the development of PH in chronic inflammatory lung diseases, which is associated with IL-6 excess in the lung (Mathew, 2010 , Pullamsetti et al., 2011 . Therefore, PVSMCs might represent suitable targets in alternative therapies for infection-induced exacerbations of chronic inflammatory lung diseases, for example, to reduce the risk of developing PH.
Although PVSMCs do not express mCD14 (Yang et al., 2005) and were stimulated in sCD14-free medium, they responded almost equally to S-LPS and Re-LPS. As CD14 mRNA is detectable in PVSMCs (Yang et al.; 2005;  this study) we hypothesized that endogenously released sCD14 might functionally replace mCD14. This was confirmed by data showing that sCD14 is constitutively released by PVSMCs and that sCD14 neutralization abolishes S-LPSinduced cytokine release. There are two ways how cells can produce sCD14. First, they can produce sCD14 by shedding from mCD14, which is attached via a glycosylphosphatidylinositol-anchor to the outside of the plasma membrane (Bufler at al., 1995) . This protease-dependent mechanism is primarily found on activated cells and probably does not apply to PVSMCs because they do not carry mCD14. Second, cells can produce sCD14 by proteaseindependent mechanisms-these are based on intracellular post-translational mechanisms, allowing CD14 to escape from the glycosylphosphatidylinositol-anchoring mechanism and to become directly secreted (Bufler at al., 1995) . This mechanism is suggested to primarily trigger constitutive sCD14 release and, therefore, might apply to the constitutive and LPSindependent sCD14 release from PVSMCs.
ERAs have been approved for therapy in PH but are also being considered for chronic inflammatory lung diseases. As endothelin has potent inflammatory potential, ERAs are believed to have anti-inflammatory properties. Experimental research supported this hypothesis, suggesting that ERAs could block the link between inflammation and remodeling (Teder and Noble, 2000; Knobloch et al., 2009 Knobloch et al., , 2013 . Recent clinical trials, however, failed to provide evidence for a utility of ERAs in inflammation-associated chronic lung diseases, such as idiopathic pulmonary fibrosis, severe asthma, or severe COPD, when administered at late disease stages with extensive tissue remodeling (Stolz et al., 2008; King et al., 2011) . However, we believe that ERAs would have to be administered at early disease stages, characterized by airway inflammation but without extensive fibrosis or emphysema, to use a putative interference of ERAs with inflammationinduced remodeling. Here, we investigated by the use of ex vivo cultivated primary PVSMCs, whether ERAs have potential to counteract the amplification of inflammation induced by bacterial infections during exacerbations of chronic lung diseases. We showed that ERAs reduce cytokine release from PVSMCs activated with the bacterial endotoxin LPS. We used ambrisentan and bosentan at concentrations of 0.1-10 mM in PVSMC culture. This resembles peak plasma concentrations of bosentan (∼1-2 mM) in vivo when taken twice daily at dosages of 62.5 or 125 mg per tablet (Treiber et al., 2007) .
The ET A R-selective inhibitor ambrisentan only suppressed IL-6, whereas specific ET B R as well as dual blockade additionally suppressed IL-8 and GM-CSF. This indicates divergent roles for ET A R and ET B R in the upregulation of cytokines by LPS and might render ET A R antagonism interesting for therapy requiring selective IL-6 downregulation. IL-6 produced by airway cells is currently discussed as a major inflammatory mediator triggering the development of comorbidities in COPD (Barnes and Celli, 2009 ). Our cell culture data provide first indication that ET A R antagonism might be useful in this context. However, at high concentrations, ambrisentan nonsignificantly upregulated IL-8 and GM-CSF by trend. Translated to putative therapy, this indicates an increase in associated inflammatory processes at high ambrisentan dosages, which might promote chronic inflammation. This would have to be balanced with a possible benefit of IL-6 downregulation.
To therapeutically reduce chronic inflammation, e.g., in COPD, the development of approaches targeting a broad Fig. 2 . LPS induces IL-8 release via TLR4. Cultivated PVSMCs were preincubated with the LPS-neutralizing drug polymyxin B (PB), with the specific TLR4 inhibitor CLI-095 (1 mM), with a neutralizing antibody against TLR2 (aTLR2AB), or a control antibody (both at 10 mg/ml) or with the TLR9 inhibitor ODN TTAGGG (2.5 mM) 30 minutes (drugs and nucleotides) or 60 minutes (antibodies) before stimulation with M-LPS (1 mg/ml). After 72 hours, IL-8 was measured in the supernatant via ELISA. Data were calculated as percent reduction versus stimulation with M-LPS alone (LPS max ). Data of PVSMCs from n = 4 donors are presented as mean 6 S.E.M. One sample t tests versus a hypothetical value 0 (= no inhibition/LPS max ) with Bonferroni correction for multiple testing: *P , 0.05; **P , 0.01; ***P , 0.001. Fig. 3 . ERAs reduce cytokine release in M-LPSstimulated PVSMCs. Cultivated PVSMCs were preincubated with ambrisentan, bosentan, or BQ788 at 100 nM-10 mM 2 hours before stimulation with M-LPS at 1 mg/ml. After 72 hours, cytokines were measured in the supernatant via ELISA. Data were calculated as percent reduction (negative values) versus stimulation with M-LPS alone (LPS max ). Data (n = 5 for IL-6 and GM-CSF; n = 6 for IL-8) are presented as mean 6 S.E.M. Curves were created by nonlinear regression analyses with sigmoidal curve fit using variable slopes. r 2 (goodness of fit): ambrisentan, 0.67; bosentan, 0.60; BQ788, 0.53 (A); ambrisentan, 0.22; bosentan, 0.42; BQ788, 0.41 (B); ambrisentan, 0.39; bosentan, 0.53; BQ788, 0.34 (C). One sample t tests versus a hypothetical value 0 (= no inhibition/LPS max ) with Bonferroni correction for multiple testing: M-LPS + ambrisentan versus LPS max : xxxP , 0.001; M-LPS + bosentan versus LPS max : *P , 0.005; **P , 0.01; ***P , 0.001; M-LPS + BQ788 versus LPS max : +P , 0.05; ++P , 0.01. One-way repeated-measures ANOVA (in each case P , 0.001 for comparisons of drug effects at 10 26 or 10 25 M, respectively, in B and C) and post hoc Bonferroni-Holm tests: M-LPS + ambrisentan versus M-LPS + bosentan: ##P , 0.01; ###P , 0.001; M-LPS + ambrisentan versus M-LPS + BQ788: ƒƒP , 0.01; ƒƒƒP , 0.001.
Endothelin Receptor Antagonists Suppress LPS Responses
spectrum of cytokines might be more auspicious, because therapeutic neutralization of single mediators has been proven to be ineffective because of functional redundancy of inflammatory proteins (Barnes, 2008b) . In this context, selective ET B R or a combined ET A R/ET B R blockade might have more putative therapeutic potential, because BQ788 as well as bosentan were both able to reduce not only IL-6 but also IL-8 and GM-CSF. IL-6, IL-8, and GM-CSF are believed to be important for the link between airway inflammation and remodeling (Knobloch et al., 2009; Mathew, 2010 , Pullamsetti et al., 2011 . Therefore, targeting the ET B R might not only have broader anti-inflammatory properties but also more potential to attenuate remodeling than selective ET A R blockade. Remodeling processes in part are mediated by PVSMCs, for example, when chronic inflammatory lung diseases become associated with PH (Barbera and Blanco, 2009; Al-Muhsen et al., 2011) . ET B R-selective inhibitors have not yet been successfully developed for therapy, but our data indicate that dual blockers might have similar anti-inflammatory properties.
A direct molecular link between endothelin receptors and LPS/TLR4 signaling has not yet been reported. This raises the question of mechanisms, by which ERAs could interfere with LPS-induced cytokine release in PVSMCs. In bronchial smooth muscle cells, ERAs suppress TNFa-induced GM-CSF release by an indirect mechanism: ERAs suppress an endothelin-1 autoregulatory feedback mechanism, which is activated by TNFa and is crucial for maintenance but not for initiation of TNFa-induced GM-CSF transcription. Thus, ERAs reduce TNFa-induced long-time but not short-time GM-CSF expression (Knobloch et al., 2009) . We expected a similar kind of indirect mechanism to be responsible for cytokine suppression by ERAs in LPS-exposed PVSMCs. Therefore, we performed long-time cell culture experiments with 72 hours of stimulation for the investigation of drug effects. We provided evidence that inhibition of ET B R activity leads to the downregulation of constitutive sCD14 secretion by PVSMCs. Cytokine expression induced by long LPS forms depend on sCD14 in PVSMCs. Therefore, sCD14 reduction caused by ET B R inactivation is a reasonable mechanistic explanation for the suppression of LPS-induced cytokine release by dual and ET B R-specific inhibitors. In support of this, we demonstrated clear effects of bosentan and BQ788 on IL-8 release induced by S-LPS, but did not find significant effects of these ERAs on IL-8 release induced by Re-LPS, which activates TLR4 independent from CD14 (Huber et al., 2006) . Thus, a putative utility of ERAs in infection-induced exacerbations could depend on the bacteria involved; for example, ERAs could be useful for infections with P. aeruginosa, which synthesizes long LPS forms (Bantroch et al.,1994; King et al., 2009) , rather than for infections with nontypeable Haemophilus influenzae, which exclusively produces short LPS forms (Schweda et al., 2007) . However, how ET A R inactivation is coupled to IL-6 suppression and possible IL-8 and GM-CSF upregulation mechanistically remains to be explained.
PVSMCs release sCD14 at concentrations of ∼700 pg/ml after 72 hours of cultivation. This might appear as a rather low sCD14 concentration in terms of adopting mCD14 functions in LPS/CD14/TLR4 signaling, considering that S-LPS induces a robust IL-6 and IL-8 production at ∼4.5 or 6 ng/ml, respectively, in PVSMCs after 72 hours of stimulation. For example, the addition of 5 ng/ml recombinant sCD14 was Fig. 5 . CD14 neutralization reduces S-LPS-induced cytokine release from PVSMCs. Cultivated PVSMCs were preincubated with a CD14 blocking antibody (clone biG14) or an isotype control 1 hour before stimulation with S-LPS (1 mg/ml) for 72 hours. Cytokines were measured in culture supernatants via ELISA. Data (n = 4) are presented as mean 6 S.E.M. Data were analyzed with one-way repeated-measures ANOVA (A, P = 0.0018; B and C, P , 0.0001) and post hoc Bonferroni-Holm tests: *P , 0.05; **P , 0.01; ***P , 0.001. Fig. 6 . Bosentan and BQ788 reduce S-LPS-but not Re-LPS-induced IL-8 release from PVSMCs. Cultivated PVSMCs were preincubated with ambrisentan, bosentan, or BQ788 (all at 1 mM) 2 hours before stimulation with S-LPS (1 mg/ml) or Re-LPS (0.1 mg/ml). After 72 hours, IL-8 was measured in supernatants via ELISA. Data were calculated as percent reduction versus stimulation with S-LPS/Re-LPS alone. Data of PVSMCs from n = 6 donors are presented as mean 6 S.E.M. One-sample t tests versus a hypothetical value 0 (= no inhibition/stimulation with S-LPS/Re-LPS alone) with Bonferroni correction for multiple testing: **P , 0.01 (symbols are placed on top of bars); two-tailed, paired Student's t tests: *P , 0.05 related to values as indicated.
Endothelin Receptor Antagonists Suppress LPS Responses required to facilitate an LPS-induced release of IL-6 at ∼3 ng/ml in VSMCs of venous origin, which do not express CD14 mRNA, sCD14, and mCD14 but TLR4 (Loppnow et al., 1995) . Therefore, the low sCD14 amounts produced by PVSMCs might be close to the minimum threshold concentration required for detectable responses to S-LPS. However, considering that bosentan and BQ788 only slightly reduce sCD14 by ∼25-29%, just the fact that PVSMCs secrete low sCD14 amounts might be a prerequisite for the clear suppressive effects of bosentan and BQ788 on cytokine production. Otherwise, if sCD14 would be produced in excess, these low reductive effects of ERAs on sCD14 would likely not result in significant consequences on LPS-induced cytokine expression. Nonetheless, this suggests that PVSMCs might have increased cytokine responses to long LPS forms in vivo, where additional exogenous sources of sCD14 are available, such as activated monocytes and macrophages that enter the lung tissue during acute bacterial infections. Therefore, future studies might investigate ERA effects on sCD14 production by monocytes/macrophages to provide more arguments for a utility of ERAs in infectioninduced exacerbations of chronic lung diseases.
Limitations of the study are as follows. PVSMC preparations might contain fibroblasts and myofibroblasts, which also express endothelin receptors and cytokines and respond to LPS (Zhang et al., 2011; Ahmedat et al., 2013) . We used SMA as a marker to exclude the presence of fibroblasts in our cell culture. SMA is expressed in a filamentous pattern in smooth muscle cells (SMCs) and myofibroblasts but, if any, in a different, diffuse pattern in some fibroblast populations (Hinz et al., 2007; Singh and Hall, 2008) . The discrimination between PVSMCs and myofibroblasts in culture is difficult because there is a lack of suitable markers. Smoothelin is not expressed in myofibroblasts, definitely identifies terminally differentiated SMCs in tissue, but gets immediately lost when SMCs start to proliferate in culture (van der Loop et al., 1996) . Myofibroblasts express other canonical SMC markers such as calponin, h-caldesmon, and desmin, and SMCs can express canonical fibroblast markers like vimentin, Thy-1, and D7-FIB (Skalli et al., 1989; Gabbiani, 1992; Singh and Hall, 2008) . Although not completely unequivocal, SMMHC might be the best marker currently available for discrimination. Myofibroblasts associated with normal wound healing do not express SMMHC (Benzonana et al., 1988; Eddy et al., 1988; Gabbiani, 1992 ) but a chronic pathologic environment might induce SMMHC expression in myofibroblasts (Chiavegato et al., 1995) . As we isolate PVSMCs from healthy, tumor-free tissue, it is unlikely to have SMMHC-positive myofibroblasts in our preparations. Moreover, if myofibroblasts are SMMHC positive, the staining is rather weak, but we observed strong staining in our cell cultures, which is characteristic for SMCs (Singh and Hall, 2008) . Finally, cultured SMCs might dedifferentiate and gain characteristics of myofibroblasts (Singh and Hall, 2008) . We exclusively used early passages and did not observe significant changes in cytokine responses to our stimulants when comparing different passages of one donor (unpublished observation). We conclude that by phenotyping with SMA and SMMHC and by using early passages, we have done the best that is currently possible to exclude the presence of significant amounts of (myo)fibroblasts in our PVSMC cultures.
In summary, we showed that ET B R blockade reduces LPSinduced cytokine production in PVSMCs attributable to sCD14 suppression. Therefore, we provide the first evidence by means of data obtained from primary cell culture experiments that specific ET B R blockade or dual blockers might attenuate inflammation in bacterial infection-induced exacerbations of chronic lung diseases. However, before this idea might be considered for clinical trials, it requires further experimental support, e.g., by investigating the sensitivity of additional cytokines to ERAs in different cell culture and animal models of bacterial infection and chronic lung diseases.
